莫西沙星与头孢哌酮/舒巴坦钠治疗社区获得性肺炎的最小成本分析

目的:评价注射用头孢哌酮/舒巴坦钠与莫西沙星注射液治疗社区获得性肺炎的经济学效果。方法:采用随机分组的研究方法,选择92例社区获得性肺炎患者,分别给予注射用头孢哌酮/舒巴坦钠(A组)、莫西沙星注射液(B组)治疗。观察2组的临床疗效、安全性,并进行药物经济学分析。结果:A组与B组有效率分别为86.00%、92.86%(P>0.05),平均成本分别为1314.8、3306.5元(P<0.05)。结论:A组方案较经济。

Cost- Minimization Analysis of Cefoperazone/Sulbactam Sodium vs. Moxifloxacin in the Treatment of Community Acquired Pneumonia

OBJECTIVE： To evaluate the economic effects of cefoperazone/ sulbactam sodium and moxifloxacin for community acquired pneumonia. METHODS： 92 patients with community acquired pneumonia were randomly assigned to receive eefoperazone/ sulbaetam sodium for injection（Group A） or moxifloxacin injection（Group B）, respectively. In both groups the observation of curative effects and safety and the pharmacoeconomic analysis were conducted. RESULTS： The effective rates of two groups were 86.00% and 92.86% （P 〉0.05）, respectively. The average cost was 1314.8 yuan in Group A versus 3 306.5 yuan in Group B（P 〈 0.05）. CONCLUSION： The therapy of Group A is more benefit between two groups.